Early evening session: The new drug discovery paradigm

R. Strieter (Cambridge, United States of America)

Source: Lung Science Conference 2014 - Lung Inflammation and Immunity
Number: 12

PDF journal article, handout or slidesSlide presentationWebcastMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Strieter (Cambridge, United States of America). Early evening session: The new drug discovery paradigm. Lung Science Conference 2014 - Lung Inflammation and Immunity

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
From the bedside: upcoming new clinical strategies
Source: International Congress 2016 – Scientific Year in Review 2016
Year: 2016

The new era of diagnostics: will it ever start?
Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship
Year: 2019

Novel capsaicin challenge methodology: a new diagnostic endpoint?
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020

Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Learning platform for smoking cessation project: From begining to date
Source: Annual Congress 2012 - Tobacco cessation and tobacco cessation services
Year: 2012

Late Breaking Abstract - Early exploratory use of omic approaches to assess metabolite changes in COPD
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020

Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects
Source: International Congress 2017 – In the frontline of the fight against tuberculosis
Year: 2017

NORDSTAR: paving the way for a new era in asthma research
Source: Eur Respir J, 55 (4) 1902476; 10.1183/13993003.02476-2019
Year: 2020

Mannitol: a new development in challenge testing
Source: Annual Congress 2012 - New ATS/ERS recommendations for bronchoprovocation challenge testing
Year: 2012

From Bench to edside: Development of a drug to treat lung disease from a basic research start
Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Year: 2009

Exploring new frontiers: the role of simulation as an educational strategy
Source: Breathe 2013; 9: 497-501
Year: 2013

Smoking cessation using innovative techniques: course report
Source: Breathe 2015; 11: 255-256
Year: 2015

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020

What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis
Source: Eur Respir Monogr 2018; 82: 414-429
Year: 2018

Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
Source: Eur Respir Rev, 27 (148) 180004; 10.1183/16000617.0004-2018
Year: 2018